GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology

For over a decade, obesity has been recognized as a well-established risk factor for the development of several cancers. Although epidemiologic studies have consistently linked excess adiposity to increased cancer incidence, obesity was rarely considered a therapeutic target within cancer care. Instead, research efforts focused largely on tumor genomics, targeted therapies, and immunotherapy, while metabolic health remained largely confined to discussions of prevention. That paradigm may be changing.

An expanding body of evidence suggests that obesity is not only a predisposing condition, but also a biologically active contributor to cancer progression. Chronic inflammation, insulin resistance, immune dysregulation, and altered metabolic signaling are increasingly understood as important drivers of tumor biology. As our understanding of these mechanisms has evolved, so too has interest in metabo-oncology, defined as the study of how host metabolism influences cancer risk, progression, treatment response, and survivorship.

In this context, few therapeutic classes have generated as much recent attention as glucagon-like peptide-1 (GLP-1) receptor agonists. Originally developed for type 2 diabetes and now widely used for obesity treatment, these agents became an unexpected focus of discussion at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Multiple presentations explored the relationship between GLP-1 receptor agonists and cancer incidence, progression, and survival across a variety of malignancies.^1-4 Although many headlines focused on the possibility that GLP-1 receptor agonists may reduce cancer risk or improve outcomes, the more important message was the importance of metabolic health in cancer biology.

Among the most discussed presentations was a propensity-matched analysis of more than 12,000 patients with obesity-related cancers. Investigators reported that GLP-1 receptor agonist use following cancer diagnosis was associated with lower rates of progression to metastatic disease in several malignancies, including breast, colorectal, lung, and hepatocellular cancers.¹ Other studies reported associations between GLP-1 receptor agonist use and lower breast cancer incidence, as well as improved overall survival across multiple tumor types.^2-4

These findings are provocative, but they should be interpreted with appropriate caution because they were largely retrospective and observational. While such analyses are valuable for generating hypotheses, they cannot establish causality. Global weight loss, changes in specific metabolic parameters, lifestyle, body composition, differences in health care utilization, and other unmeasured factors may contribute to the observed associations. Prospective randomized studies will be necessary to address whether and how GLP-1 receptor agonists could be incorporated into cancer treatment.⁴

Nevertheless, the significance of these studies extends beyond any individual drug class. Collectively, they reinforce a broader concept that has gained momentum in recent years: Cancer does not develop in isolation from host physiology. Metabolism, body composition, nutrition, physical activity, and systemic inflammation all influence the environment in which tumors arise and evolve. As a result, interventions that modify these factors may ultimately become important therapeutic components of conventional cancer therapies.

For practicing oncologists, the immediate implications are limited. The current evidence does not support prescribing GLP-1 receptor agonists specifically to prevent cancer progression or improve cancer outcomes, and safety data in the context of cancer treatment are urgently needed. However, the data presented at ASCO 2026 should encourage us to think more broadly about the role of metabolic health across the cancer continuum. Obesity management, physical activity, nutrition, and cardiometabolic health are important components of comprehensive cancer care, not only for prevention and survivorship but potentially as cancer therapy.

Perhaps the most important lesson from ASCO 2026 is not that GLP-1 receptor agonists could be developed as anticancer agents. Rather, these studies have brought renewed attention to a fundamental question: To what extent can improving metabolic health alter the trajectory of cancer itself?

The answer remains uncertain. Yet as the field continues to advance, it is becoming increasingly clear that metabolic health belongs alongside genomics, immunology, and targeted therapeutics as a critical area of novel cancer therapeutic strategies. Just as oncologists have needed to renew their understanding of immunology to optimally deploy immunotherapy, it may soon be time to follow a similar approach to incorporating metabolic therapies. The challenge now is to move beyond provocative associations and generate the prospective evidence needed to determine whether interventions targeting metabolic dysfunction can meaningfully improve cancer-specific outcomes.

References

1. Orland MD, Mandala A, Unlu S, et al. Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. J Clin Oncol. 2026;44(suppl 16):3143. doi:10.1200/JCO.2026.44.16_suppl.3143
2. McDonald ES, Gillis LB, Gabriel P, et al. Association of GLP-1 agonists with breast cancer incidence in women. J Clin Oncol. 2026;44(suppl 16):10506. doi:10.1200/JCO.2026.44.16_suppl.10506
3. McDonald ES, Gillis LB, Gabriel P, et al. GLP-1 Agonists are associated with a significant reduction in breast cancer incidence in women. JCO Oncol Pract. Published online June 2, 2026. doi:10.1200/OP-26-00485
4. Sruti I, Wentworth C, Marcus A, Su Z, Paulus JK. GLP-1 receptor agonist utilization and survival outcomes in a large U.S. community oncology cohort. J Clin Oncol. 2026;44(suppl 16):11017.doi:10.1200/JCO.2026.44.16_suppl.11017